Calendario›VSTM›PF00562271

PF00562271

Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms

Ensayo de Verastem, Inc. en Head and Neck Neoplasm · Prostatic Neoplasm · Pancreatic Neoplasm (del registro, en inglés).

Fase

Fase 1

Estado

Completado

Participantes

99

previstos

Centros

4

Fin del objetivo primario

abr 2009

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en dic 2005.

Qué mide

Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) (Baseline up to Cycle 1 Day 21 (C1.D21)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroPhase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography \[PET\] scans due to advanced non-hematologic malignancies, including pancreatic, head and neck, and prostatic neoplasms, and patients with other malignancies appropriate for serial biopsy. Screening consists of a Fluorodeoxyglucose Positron Emission Tomography \[FDG-PET\] and tumor imaging, medical history, physical examination, Eastern Cooperative Oncology Group \[ECOG\] performance status, blood draws, a pregnancy test for female patients of childbearing potential. Treatment consists of PF00562271 tablets continued until progression of disease, unacceptable toxicity, or patient request. Evaluations for bioactivity are measured by serial FDG-PET and blood tests for biomarkers related to FAK and PYK2 kinase activities.

Más ensayos de VSTM

Todos los de VSTM, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00666926), actualizada en mar 2013.